Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price Target & Predictions
AMPH Stock Forecast
Amphastar Pharmaceuticals stock forecast is as follows: an average price target of $66.00 (represents a 30.10% upside from AMPH’s last price of $50.73) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
AMPH Price Target
AMPH Analyst Ratings
Amphastar Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 08, 2024 | David Amsellem | Piper Sandler | $66.00 | $43.30 | 52.41% | 30.10% |
May 23, 2024 | David Amsellem | Piper Sandler | $71.00 | $43.31 | 63.93% | 39.96% |
Mar 12, 2022 | David Amsellem | Piper Sandler | $35.00 | $34.30 | 2.04% | -31.01% |
Amphastar Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 2 |
Avg Price Target | - | $66.00 | $68.50 |
Last Closing Price | $50.73 | $50.73 | $50.73 |
Upside/Downside | -100.00% | 30.10% | 35.03% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jun 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
May 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Mar 12, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Amphastar Pharmaceuticals Financial Forecast
Amphastar Pharmaceuticals Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $155.65M | - | $145.71M | $140.02M | $135.02M | $120.13M | $123.47M | $120.37M | $120.89M | $112.20M | $101.66M | $103.02M | $95.92M | $83.43M | $85.81M | $84.69M | $83.38M | $80.14M | $79.05M | $79.79M | $58.39M | $56.67M |
Avg Forecast | $219.76M | $216.01M | $198.58M | $189.95M | $197.54M | $194.67M | $170.96M | $174.65M | $173.43M | $174.63M | $137.27M | $137.27M | $127.18M | $125.98M | $118.08M | $113.33M | $111.62M | $103.25M | $101.30M | $96.87M | $88.94M | $91.23M | $86.73M | $82.90M | $81.81M | $78.57M | $77.56M | $76.22M | $93.42M | $44.08M |
High Forecast | $219.76M | $216.01M | $198.58M | $189.95M | $197.54M | $203.17M | $170.96M | $174.65M | $182.05M | $174.63M | $137.27M | $137.27M | $127.18M | $125.98M | $118.08M | $113.33M | $111.62M | $103.25M | $101.30M | $96.87M | $88.94M | $91.23M | $86.73M | $82.90M | $81.81M | $78.57M | $77.56M | $76.22M | $112.11M | $52.89M |
Low Forecast | $219.76M | $216.01M | $198.58M | $189.95M | $197.54M | $187.01M | $170.96M | $174.65M | $164.80M | $174.63M | $137.27M | $137.27M | $127.18M | $125.98M | $118.08M | $113.33M | $111.62M | $103.25M | $101.30M | $96.87M | $88.94M | $91.23M | $86.73M | $82.90M | $81.81M | $78.57M | $77.56M | $76.22M | $74.74M | $35.26M |
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
Surprise % | - | - | - | - | - | - | - | - | 0.90% | - | 1.06% | 1.02% | 1.06% | 0.95% | 1.05% | 1.06% | 1.08% | 1.09% | 1.00% | 1.06% | 1.08% | 0.91% | 0.99% | 1.02% | 1.02% | 1.02% | 1.02% | 1.05% | 0.63% | 1.29% |
Amphastar Pharmaceuticals EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
EBITDA | - | - | - | - | - | - | - | - | $53.98M | - | $36.90M | $33.43M | $37.83M | $23.23M | $24.82M | $36.18M | $33.67M | $43.27M | $20.31M | $13.13M | $-365.00K | $13.05M | $5.69M | $12.13M | $5.08M | $7.20M | $67.69M | $3.94M | $-5.08M | $5.52M |
Avg Forecast | $34.33M | $33.74M | $31.02M | $29.67M | $30.85M | $30.41M | $26.70M | $27.28M | $27.09M | $27.28M | $21.44M | $21.44M | $19.87M | $19.68M | $18.44M | $24.64M | $17.43M | $16.13M | $15.82M | $7.22M | $13.89M | $14.25M | $13.55M | $11.19M | $12.78M | $12.27M | $12.12M | $2.17M | $-12.01M | $3.94M |
High Forecast | $34.33M | $33.74M | $31.02M | $29.67M | $30.85M | $31.73M | $26.70M | $27.28M | $28.44M | $27.28M | $21.44M | $21.44M | $19.87M | $19.68M | $18.44M | $29.57M | $17.43M | $16.13M | $15.82M | $8.66M | $13.89M | $14.25M | $13.55M | $13.43M | $12.78M | $12.27M | $12.12M | $2.60M | $-9.60M | $4.73M |
Low Forecast | $34.33M | $33.74M | $31.02M | $29.67M | $30.85M | $29.21M | $26.70M | $27.28M | $25.74M | $27.28M | $21.44M | $21.44M | $19.87M | $19.68M | $18.44M | $19.71M | $17.43M | $16.13M | $15.82M | $5.78M | $13.89M | $14.25M | $13.55M | $8.95M | $12.78M | $12.27M | $12.12M | $1.73M | $-14.41M | $3.15M |
Surprise % | - | - | - | - | - | - | - | - | 1.99% | - | 1.72% | 1.56% | 1.90% | 1.18% | 1.35% | 1.47% | 1.93% | 2.68% | 1.28% | 1.82% | -0.03% | 0.92% | 0.42% | 1.08% | 0.40% | 0.59% | 5.59% | 1.82% | 0.42% | 1.40% |
Amphastar Pharmaceuticals Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
Net Income | - | - | - | - | - | - | - | - | $36.17M | - | $26.12M | $26.03M | $33.91M | $15.87M | $17.35M | $24.25M | $19.97M | $29.55M | $7.77M | $5.04M | $-6.27M | $3.92M | $-192.00K | $3.95M | $-1.03M | $1.31M | $47.79M | $868.00K | $-7.25M | $893.00K |
Avg Forecast | $65.98M | $62.46M | $55.55M | $52.35M | $51.94M | $51.42M | $40.20M | $40.25M | $47.34M | $36.17M | $29.14M | $27.67M | $20.82M | $20.47M | $18.11M | $16.84M | $19.26M | $12.49M | $10.93M | $2.77M | $7.14M | $7.29M | $7.06M | $3.64M | $3.90M | $3.47M | $1.82M | $477.40K | $-17.12M | $637.86K |
High Forecast | $65.98M | $62.46M | $55.55M | $52.35M | $51.94M | $56.41M | $40.21M | $40.26M | $52.78M | $36.17M | $29.14M | $27.67M | $20.82M | $20.47M | $18.11M | $20.21M | $19.26M | $12.49M | $10.93M | $3.33M | $7.14M | $7.29M | $7.06M | $4.37M | $3.90M | $3.47M | $1.82M | $572.88K | $-13.69M | $765.43K |
Low Forecast | $65.98M | $62.46M | $55.55M | $52.35M | $51.94M | $45.43M | $40.19M | $40.24M | $40.81M | $36.17M | $29.14M | $27.67M | $20.82M | $20.47M | $18.11M | $13.47M | $19.26M | $12.49M | $10.93M | $2.22M | $7.14M | $7.29M | $7.06M | $2.91M | $3.90M | $3.47M | $1.82M | $381.92K | $-20.54M | $510.29K |
Surprise % | - | - | - | - | - | - | - | - | 0.76% | - | 0.90% | 0.94% | 1.63% | 0.78% | 0.96% | 1.44% | 1.04% | 2.37% | 0.71% | 1.82% | -0.88% | 0.54% | -0.03% | 1.08% | -0.26% | 0.38% | 26.23% | 1.82% | 0.42% | 1.40% |
Amphastar Pharmaceuticals SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
SG&A | - | - | - | - | - | - | - | - | $21.74M | - | $19.00M | $20.59M | $16.10M | $16.77M | $15.73M | $17.99M | $14.70M | $15.65M | $18.69M | $19.88M | $15.82M | $15.35M | $19.95M | $14.04M | $13.98M | $14.24M | $15.42M | $19.47M | $12.72M | $12.82M |
Avg Forecast | $35.06M | $34.46M | $31.68M | $30.30M | $31.51M | $31.06M | $27.27M | $27.86M | $27.67M | $27.86M | $21.90M | $21.90M | $20.29M | $20.10M | $18.84M | $12.49M | $17.81M | $16.47M | $16.16M | $10.93M | $14.19M | $14.55M | $13.84M | $12.95M | $13.05M | $12.53M | $12.37M | $10.71M | $30.05M | $9.15M |
High Forecast | $35.06M | $34.46M | $31.68M | $30.30M | $31.51M | $32.41M | $27.27M | $27.86M | $29.04M | $27.86M | $21.90M | $21.90M | $20.29M | $20.10M | $18.84M | $14.99M | $17.81M | $16.47M | $16.16M | $13.12M | $14.19M | $14.55M | $13.84M | $15.54M | $13.05M | $12.53M | $12.37M | $12.85M | $36.06M | $10.99M |
Low Forecast | $35.06M | $34.46M | $31.68M | $30.30M | $31.51M | $29.83M | $27.27M | $27.86M | $26.29M | $27.86M | $21.90M | $21.90M | $20.29M | $20.10M | $18.84M | $9.99M | $17.81M | $16.47M | $16.16M | $8.74M | $14.19M | $14.55M | $13.84M | $10.36M | $13.05M | $12.53M | $12.37M | $8.57M | $24.04M | $7.32M |
Surprise % | - | - | - | - | - | - | - | - | 0.79% | - | 0.87% | 0.94% | 0.79% | 0.83% | 0.84% | 1.44% | 0.83% | 0.95% | 1.16% | 1.82% | 1.11% | 1.05% | 1.44% | 1.08% | 1.07% | 1.14% | 1.25% | 1.82% | 0.42% | 1.40% |
Amphastar Pharmaceuticals EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
EPS | - | - | - | - | - | - | - | - | $0.68 | - | $0.54 | $0.54 | $0.70 | $0.32 | $0.35 | $0.50 | $0.42 | $0.62 | $0.16 | $0.11 | $-0.13 | $0.08 | - | $0.09 | $-0.02 | $0.03 | $1.01 | $0.02 | $-0.16 | $0.02 |
Avg Forecast | $1.27 | $1.20 | $1.07 | $1.01 | $1.00 | $0.99 | $0.77 | $0.77 | $0.91 | $0.69 | $0.56 | $0.53 | $0.40 | $0.39 | $0.35 | $0.36 | $0.37 | $0.24 | $0.21 | $0.18 | $0.14 | $0.14 | $0.14 | $0.09 | $0.07 | $0.07 | $0.04 | $0.04 | $0.19 | $0.05 |
High Forecast | $1.27 | $1.20 | $1.07 | $1.01 | $1.00 | $1.08 | $0.77 | $0.77 | $1.01 | $0.69 | $0.56 | $0.53 | $0.40 | $0.39 | $0.35 | $0.36 | $0.37 | $0.24 | $0.21 | $0.18 | $0.14 | $0.14 | $0.14 | $0.09 | $0.07 | $0.07 | $0.04 | $0.04 | $0.23 | $0.06 |
Low Forecast | $1.27 | $1.20 | $1.07 | $1.01 | $1.00 | $0.87 | $0.77 | $0.77 | $0.78 | $0.69 | $0.56 | $0.53 | $0.40 | $0.39 | $0.35 | $0.36 | $0.37 | $0.24 | $0.21 | $0.18 | $0.14 | $0.14 | $0.14 | $0.09 | $0.07 | $0.07 | $0.04 | $0.04 | $0.15 | $0.04 |
Surprise % | - | - | - | - | - | - | - | - | 0.75% | - | 0.96% | 1.02% | 1.75% | 0.81% | 1.01% | 1.39% | 1.14% | 2.58% | 0.76% | 0.60% | -0.95% | 0.57% | - | 1.05% | -0.27% | 0.45% | 28.86% | 0.50% | -0.84% | 0.40% |
Amphastar Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IRWD | Ironwood Pharmaceuticals | $4.19 | $11.67 | 178.52% | Buy |
PCRX | Pacira BioSciences | $16.57 | $40.00 | 141.40% | Hold |
EVO | Evotec SE | $3.88 | $8.00 | 106.19% | Buy |
EOLS | Evolus | $16.75 | $24.00 | 43.28% | Buy |
ANIP | ANI Pharmaceuticals | $58.19 | $79.00 | 35.76% | Buy |
AMPH | Amphastar Pharmaceuticals | $50.73 | $66.00 | 30.10% | Buy |
ALKS | Alkermes | $26.47 | $34.38 | 29.88% | Hold |
COLL | Collegium Pharmaceutical | $33.46 | $41.50 | 24.03% | Buy |
NBIX | Neurocrine Biosciences | $122.21 | $147.70 | 20.86% | Buy |
SUPN | Supernus Pharmaceuticals | $33.97 | $38.00 | 11.86% | Buy |
PBH | Prestige Consumer Healthcare | $74.05 | $82.00 | 10.74% | Buy |
DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
PAHC | Phibro Animal Health | $23.18 | $18.67 | -19.46% | Buy |
AMPH Forecast FAQ
Is Amphastar Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Amphastar Pharmaceuticals (AMPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of AMPH's total ratings.
What is AMPH's price target?
Amphastar Pharmaceuticals (AMPH) average price target is $66 with a range of $66 to $66, implying a 30.10% from its last price of $50.73. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amphastar Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AMPH stock, the company can go up by 30.10% (from the last price of $50.73 to the average price target of $66), up by 30.10% based on the highest stock price target, and up by 30.10% based on the lowest stock price target.
Can Amphastar Pharmaceuticals stock reach $80?
AMPH's average twelve months analyst stock price target of $66 does not support the claim that Amphastar Pharmaceuticals can reach $80 in the near future.
What are Amphastar Pharmaceuticals's analysts' financial forecasts?
Amphastar Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $737.82M (high $746.32M, low $730.15M), average EBITDA is $115.24M (high $116.57M, low $114.05M), average net income is $183.81M (high $188.82M, low $177.8M), average SG&A $117.71M (high $119.06M, low $116.48M), and average EPS is $3.53 (high $3.63, low $3.42). AMPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $824.3M (high $824.3M, low $824.3M), average EBITDA is $128.75M (high $128.75M, low $128.75M), average net income is $236.34M (high $236.34M, low $236.34M), average SG&A $131.5M (high $131.5M, low $131.5M), and average EPS is $4.54 (high $4.54, low $4.54).
Did the AMPH's actual financial results beat the analysts' financial forecasts?
Based on Amphastar Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $593.24M, which missed the average analysts forecast of $622.59M by -4.71%. Apple's EBITDA was $196.99M, beating the average prediction of $97.25M by 102.57%. The company's net income was $137.54M, missing the average estimation of $140.32M by -1.98%. Apple's SG&A was $80.39M, missing the average forecast of $99.32M by -19.06%. Lastly, the company's EPS was $2.6, missing the average prediction of $2.7 by -3.57%. In terms of the last quarterly report (Dec 2023), Amphastar Pharmaceuticals's revenue was $155.65M, missing the average analysts' forecast of $173.43M by -10.25%. The company's EBITDA was $53.98M, beating the average prediction of $27.09M by 99.27%. Amphastar Pharmaceuticals's net income was $36.17M, missing the average estimation of $47.34M by -23.60%. The company's SG&A was $21.74M, missing the average forecast of $27.67M by -21.42%. Lastly, the company's EPS was $0.68, missing the average prediction of $0.91 by -25.24%